Focus Equities

Novavax Shares Rise


Novavax rose more than 9% after publishing data from the second of two mid-stage trials of its vaccine candidate for respiratory syncytial virus (RSV) in women of child bearing age, which is being developed with the goal of protecting infants from RSV disease. “These data suggest that the RSV F Vaccine provided protection against RSV infection in controlled trials of over 1,000 women,” said Gregory Glenn, president of research and development at Novavax.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively, the company said.